Press Releases May 12, 2026 09:00 AM

Tenable Co-CEOs and CFO to Present at Upcoming Investor Events

Tenable's Leadership to Present at Major Investor Conferences and Host Inaugural Exposure Management Investor Day

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
TENB

Tenable Holdings, Inc., a leading exposure management company in cybersecurity, announced that its co-CEOs and CFO will present at key upcoming investor events including the J.P. Morgan Global Technology, Media and Communications Conference and the William Blair Growth Stock Conference. The company will also hold an inaugural Investor Day alongside its Exposure 2026 conference in Boston, providing insights into its AI-powered exposure management platform and strategic outlook.

Tenable Co-CEOs and CFO to Present at Upcoming Investor Events
TENB
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Tenable’s Co-CEOs and CFO to present at prominent technology and growth stock investor conferences, highlighting leadership engagement with the investment community.
  • The company is hosting its first-ever Investor Day in conjunction with a major exposure management conference, signaling a strategic push to deepen investor understanding of its business and technology.
  • Tenable’s platform focuses on reducing business risk by addressing cybersecurity gaps across IT, cloud, and critical infrastructure, relevant to sectors such as technology, cybersecurity, and enterprise IT services.

COLUMBIA, Md., May 12, 2026 (GLOBE NEWSWIRE) -- Tenable® Holdings, Inc. (NASDAQ: TENB), the exposure management company, today announced that Co-CEO Mark Thurmond and CFO Matt Brown will present at the J.P. Morgan Global Technology, Media and Communications Conference. Co-CEO Steve Vintz and Matt Brown will present at the William Blair Growth Stock Conference.

Tenable will also host an Investor Day on Thursday, May 21, 2026 in Boston, co-located with EXPOSURE 2026, its inaugural exposure management conference. Pre-registration is required. Additional details are available on the Tenable Investor Relations website.

Details for each event are as follows:

J.P. Morgan Global Technology, Media and Communications Conference
Tuesday, May 19, 2026
Boston

Tenable 2026 Investor Day
Thursday, May 21, 2026
Boston

William Blair Growth Stock Conference
Thursday, June 4, 2026
Chicago

About Tenable
Tenable® is the exposure management company, exposing and closing the cybersecurity gaps that erode business value, reputation and trust. The company’s AI-powered exposure management platform radically unifies security visibility, insight and action across the attack surface, equipping modern organizations to protect against attacks from IT infrastructure to cloud environments to critical infrastructure and everywhere in between. By protecting enterprises from security exposure, Tenable reduces business risk for over 40,000 customers around the globe. Learn more at tenable.com.

Media Contact:
Tenable
tenablepr@tenable.com


Risks

  • Potential uncertainty regarding the market’s reception of the information shared during investor presentations and the inaugural Investor Day, which could affect stock volatility.
  • Cybersecurity industry competitive landscape and evolving threats may influence Tenable’s growth prospects and investor confidence.
  • Effectiveness of Tenable’s AI-powered platform in delivering promised business risk reduction could impact customer retention and revenue growth, posing uncertainty for investors.

More from Press Releases

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress Jun 14, 2026 Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 Jun 14, 2026 Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026 Jun 14, 2026 Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control Jun 14, 2026 Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026